X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ALEMBIC PHARMA with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALEMBIC PHARMA   ACTAVIS
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
ACTAVIS
Dec-14
ALEMBIC PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs79218,752-   
Low Rs44311,438-   
Sales per share (Unadj.) Rs167.03,376.8-  
Earnings per share (Unadj.) Rs38.2-421.4-  
Cash flow per share (Unadj.) Rs42.0309.8-  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs84.97,324.1-  
Shares outstanding (eoy) m188.52265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.74.5 82.7%   
Avg P/E ratio x16.2-35.8 -45.2%  
P/CF ratio (eoy) x14.748.7 30.2%  
Price / Book Value ratio x7.32.1 352.8%  
Dividend payout %10.50-   
Avg Mkt Cap Rs m116,3834,013,841 2.9%   
No. of employees `000NA21.6 0.0%   
Total wages/salary Rs m4,2140-   
Avg. sales/employee Rs ThNM41,568.6-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-5,187.3-  
INCOME DATA
Net Sales Rs m31,487897,882 3.5%  
Other income Rs m55-2,241 -2.5%   
Total revenues Rs m31,542895,641 3.5%   
Gross profit Rs m10,060115,346 8.7%  
Depreciation Rs m722194,424 0.4%   
Interest Rs m3728,321 0.1%   
Profit before tax Rs m9,356-109,640 -8.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0-8,043 0.0%   
Tax Rs m2,160-5,637 -38.3%   
Profit after tax Rs m7,194-112,046 -6.4%  
Gross profit margin %31.912.8 248.7%  
Effective tax rate %23.15.1 449.1%   
Net profit margin %22.8-12.5 -183.1%  
BALANCE SHEET DATA
Current assets Rs m15,066473,069 3.2%   
Current liabilities Rs m7,674345,006 2.2%   
Net working cap to sales %23.514.3 164.6%  
Current ratio x2.01.4 143.2%  
Inventory Days Days6758 115.4%  
Debtors Days Days4166 61.3%  
Net fixed assets Rs m8,237109,640 7.5%   
Share capital Rs m3770-   
"Free" reserves Rs m15,4160-   
Net worth Rs m16,0051,947,473 0.8%   
Long term debt Rs m01,020,514 0.0%   
Total assets Rs m24,5943,569,077 0.7%  
Interest coverage x255.2-2.9 -8,889.1%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.30.3 508.9%   
Return on assets %29.4-2.3 -1,253.4%  
Return on equity %44.9-5.8 -781.3%  
Return on capital %58.7-3.0 -1,948.8%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Net fx Rs m12,4930-   
CASH FLOW
From Operations Rs m9,304154,184 6.0%  
From Investments Rs m-3,105-369,175 0.8%  
From Financial Activity Rs m-1,959207,423 -0.9%  
Net Cashflow Rs m4,240-7,568 -56.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 68.74 Rs / USD

Compare ALEMBIC PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare ALEMBIC PHARMA With: TORRENT PHARMA  PANACEA BIOTECH  JUBILANT LIFE SCIENCES  DR. REDDYS LAB  WOCKHARDT LTD.  



Today's Market

Of IPOs, LIC-IDBI Bank Deal, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed marginally higher on Friday last week. All sectoral indices traded in green, with stocks in the IT sector and stocks in the pharma sector, leading the gains.

Related Views On News

ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Sintex's Auditor Resigns. How You Can Protect Yourself from Such Stocks(The 5 Minute Wrapup)

Jul 20, 2018

While the attack on the bad corporate governance is an overhang in the near term...this can be a game-changer in the years to come.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

PPF v/s Mutual Funds: Which Is Better?(Outside View)

Jul 10, 2018

PersonalFN highlights the key points of distinction between PPF and mutual funds.

ICICI Pru Mutual Fund Tarakki Karega! - The Unethical Way?(Outside View)

Jul 11, 2018

PersonalFN explains how ICICI Prudential Mutual Fund flouted the norms of related party transactions while subscribing to the IPO of ICICI Securities.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jul 23, 2018 09:03 AM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS